Research

Exogenous surfactant application in a rat lung ischemia reperfusion injury model: effects on edema formation and alveolar type II cells

Niels Dreyer¹ , Christian Mühlfeld^1,2 , Antonia Fehrenbach^1,3 , Thomas Pech⁴ , Sebastian von Berg¹ , Ragi Nagib⁴ , Joachim Richter¹ , Thorsten Wittwer^4,5 , Thorsten Wahlers^4,5 and Matthias Ochs^1,2

¹  Department of Anatomy, Division of Electron Microscopy, University of Göttingen, Kreuzbergring 36, D-37075 Göttingen, Germany

²  Institute of Anatomy, University of Bern, Baltzerstrasse 2, CH-3012 Bern, Switzerland

³  Clinical Research Group "Chronic Airway Diseases", Department of Internal Medicine (Respiratory Medicine), Philipps-University, Baldingerstrasse, D-35043 Marburg, Germany

⁴  Department of Cardiothoracic and Vascular Surgery, Friedrich Schiller University, Erlanger Allee 101, D-07747 Jena, Germany

⁵  Department of Cardiothoracic Surgery, University Hospital of Cologne, Kerpener Str. 62, D-50924 Cologne, Germany

author email corresponding author email

Respiratory Research 2008, 9:5doi:10.1186/1465-9921-9-5

Published:	18 January 2008

Abstract

Background

Prophylactic exogenous surfactant therapy is a promising way to attenuate the ischemia and reperfusion (I/R) injury associated with lung transplantation and thereby to decrease the clinical occurrence of acute lung injury and acute respiratory distress syndrome. However, there is little information on the mode by which exogenous surfactant attenuates I/R injury of the lung. We hypothesized that exogenous surfactant may act by limiting pulmonary edema formation and by enhancing alveolar type II cell and lamellar body preservation. Therefore, we investigated the effect of exogenous surfactant therapy on the formation of pulmonary edema in different lung compartments and on the ultrastructure of the surfactant producing alveolar epithelial type II cells.

Methods

Rats were randomly assigned to a control, Celsior (CE) or Celsior + surfactant (CE+S) group (n = 5 each). In both Celsior groups, the lungs were flush-perfused with Celsior and subsequently exposed to 4 h of extracorporeal ischemia at 4°C and 50 min of reperfusion at 37°C. The CE+S group received an intratracheal bolus of a modified natural bovine surfactant at a dosage of 50 mg/kg body weight before flush perfusion. After reperfusion (Celsior groups) or immediately after sacrifice (Control), the lungs were fixed by vascular perfusion and processed for light and electron microscopy. Stereology was used to quantify edematous changes as well as alterations of the alveolar epithelial type II cells.

Results

Surfactant treatment decreased the intraalveolar edema formation (mean (coefficient of variation): CE: 160 mm³ (0.61) vs. CE+S: 4 mm³ (0.75); p < 0.05) and the development of atelectases (CE: 342 mm³ (0.90) vs. CE+S: 0 mm³; p < 0.05) but led to a higher degree of peribronchovascular edema (CE: 89 mm³ (0.39) vs. CE+S: 268 mm³ (0.43); p < 0.05). Alveolar type II cells were similarly swollen in CE (423 μm³(0.10)) and CE+S (481 μm³(0.10)) compared with controls (323 μm³(0.07); p < 0.05 vs. CE and CE+S). The number of lamellar bodies was increased and the mean lamellar body volume was decreased in both CE groups compared with the control group (p < 0.05).

Conclusion

Intratracheal surfactant application before I/R significantly reduces the intraalveolar edema formation and development of atelectases but leads to an increased development of peribronchovascular edema. Morphological changes of alveolar type II cells due to I/R are not affected by surfactant treatment. The beneficial effects of exogenous surfactant therapy are related to the intraalveolar activity of the exogenous surfactant.